Move over, A: B is taking the lead now, with Be Biopharma closing out a $130 million financing round backed by several industry leaders that will fuel its engineered B cells platform. The biotech aims ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback